Pulmonary Arterial Hypertension Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 26, 2019--The “Pulmonary Arterial Hypertension - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Pulmonary Arterial Hypertension - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 14, 14, 1, 38, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Aadi Bioscience Inc
- Acceleron Pharma Inc
- Actelion Pharmaceuticals Ltd
- Aerogen Ltd
- AI Therapeutics
- AVEO Pharmaceuticals Inc
- Bayer AG
- Bial - Portela & Ca SA
- Biogen Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Camurus AB
- Capricor Therapeutics Inc
- Celsion Corp
- Celtaxsys Inc
- Chiesi Farmaceutici SpA
- Chugai Pharmaceutical Co Ltd
- Complexa Inc
- Denovo Biopharma LLC
- Eli Lilly and Co
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Gossamer Bio Inc
- Insmed Inc
- Insys Therapeutics Inc
- Japan Tobacco Inc
- Liquidia Technologies Inc
- Martin Pharmaceuticals Inc
- Merck & Co Inc
- Mezzion Pharma Co Ltd
- Nippon Shinyaku Co Ltd
- Nissan Chemical Corp
- Northern Therapeutics Inc
- Novartis AG
- Peloton Therapeutics Inc
- PhaseBio Pharmaceuticals Inc
- Pulmokine Inc
- Q BioMed Inc
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- Relief Therapeutics Holding AG
- Respira Therapeutics Inc
- Resverlogix Corp
- Reviva Pharmaceuticals Inc
- SteadyMed Therapeutics Inc
- Suda Pharmaceuticals Ltd
- Takeda Pharmaceutical Co Ltd
- Toray Industries Inc
- United Therapeutics Corp
- Vicore Pharma AB
- Vivus Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/szgfgr/pulmonary?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005764/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/26/2019 12:23 PM/DISC: 03/26/2019 12:23 PM